A prospective study of nerve-sparing radical hysterectomy for uterine cervical carcinoma in Taiwan

Abstract

We concluded that the new technique of NRH can reduce postoperative bladder dysfunctions.

Clinical Efficacy and Safety of Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Systematic Review and Meta-Analysis

“…In the end, 17 studies were included in the meta-analysis (Figure 1), including 13 involving laparotomy [21]–[33] and 4 involving laparoscopy [34]–[37]. Of these 17, 10 were conducted in mainland China [24], [25], [28], [29], [31], [32], [34]–[37], one in Taiwan [33], two in Japan [21], [23], two in Italy [22], [30], one in Poland [27] and one in the Netherlands [26].…”

“…Of these 17, 10 were conducted in mainland China [24], [25], [28], [29], [31], [32], [34]–[37], one in Taiwan [33], two in Japan [21], [23], two in Italy [22], [30], one in Poland [27] and one in the Netherlands [26]. One study included three groups [22], so we extracted only the data for the Type III NSRH group and the Type III RH group.…”

Oncological Outcomes of Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Systematic Review

“…[9][10][11][12][13][14][26][27][28][29] Most of these comparison studies had a small sample size (\50 patients with NSRH). [10][11][12]26,27,29 However, the groups in the larger studies also were mostly noncomparable for several reasons: (1) two of the largest trials used historical cohorts 14,28 ; (2) in one study, only patients with worse prognostic factors were referred to CRH 13 ; and (3) in another relatively larger study, the adjuvant treatment strategy of the study cohorts was not clearly identified. 19 Moreover, only three comparison trials 13,14,28 reported the effect estimates of NSRH, which were few and heterogeneous and thus precluded a standard meta-analysis or weighted pooling of results due to a severe risk of bias.…”

“…16 Thus, we were able to find seven retrospective studies focused mainly on oncologic outcomes of NSRH. 11,13,14,17,23,24,28 Outcomes Our literature search found heterogeneous oncologic outcomes ranging from no overall recurrences 15,17,19,20,22,25,27,29 to an overall recurrence rate of 19.6 % 28 after NSRH.…”

“…Five studies 12,19,26,27,29 recorded no recurrences or only one recurrence, precluding the possibility of obtaining a reliable estimate of the effect measure. One study 10 did not report any results on recurrence.…”